Therefore, different inhibitors are currently being studied in several tumor types as co-administered with anti-PD-1 antibodies (i.e., nivolumab or pembrolizumab) or anti-PD-L1 antibodies (i.e., atezolizumab or durvalumab)[166] and the same approach is to be envisaged for ICIs-resistant CRCs. This evidence concerns the gene PDCD1 and neoplasm.